Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

NCT06605586 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Tasquinimod

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland